[
  {
    "ts": null,
    "headline": "Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects",
    "summary": "Incyte Corporation (NASDAQ:INCY) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 15, UBS reiterated a ‘Neutral’ rating on the stock and increased its price target to $62 from $61. The price hike comes as UBS expects higher sales for Incyte’s Niktimvo, a treatment for chronic Graft-versus-Host Disease […]",
    "url": "https://finnhub.io/api/news?id=c843cbb2c6939eb960a7227fa71eb7557c9ddf8b84b150d78ab455daa8259a8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753415269,
      "headline": "Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects",
      "id": 136085790,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte Corporation (NASDAQ:INCY) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 15, UBS reiterated a ‘Neutral’ rating on the stock and increased its price target to $62 from $61. The price hike comes as UBS expects higher sales for Incyte’s Niktimvo, a treatment for chronic Graft-versus-Host Disease […]",
      "url": "https://finnhub.io/api/news?id=c843cbb2c6939eb960a7227fa71eb7557c9ddf8b84b150d78ab455daa8259a8c"
    }
  }
]